The use of proton pump inhibitors in patients with a previous hip fracture is associated with increased risk for recurrent hip fracture, except with very low doses.
Community-dwelling patients with Alzheimer disease (AD) experience a lower risk for fractures, including hip fractures, with thiazide use.
Abaloparatide followed by alendronate treatment may improve bone mineral density in women with postmenopausal osteoporosis and type 2 diabetes.
Type 2 diabetes is associated with increased risk for fractures in the short term but not in the long term.
Long-term osteoporosis drug therapy reduces fracture risk in women but may increase risk for rare adverse events, and research gaps surround use of long-term drug therapies for osteoporotic fracture prevention.
Rates of osteoporosis screening and treatment are low in patients with recent stroke despite elevated risk for low-trauma fracture.
Cortical bidirectional axial transmission measurements may be useful for fracture risk assessment in postmenopausal women.
A meta-analysis showed that abaloparatide treatment reduces the risk for vertebral, nonvertebral, and wrist fractures in postmenopausal women with osteoporosis compared with placebo or other medical treatments.
Overall, treatments that were associated with the greatest relative risk reduction in fragility fractures included teriparatide, abaloparatide, denosumab, romosozumab and most bisphosphonate.
In elderly patients with COPD, rapid decline in bone mineral density is associated with an increased risk for vertebral fracture.
